Radix astragali seu hedysari pulse-activating decoction capable of preventing radiation-induced heart injury

Abstract

The invention provides a pharmacological mechanism of radix astragali seu hedysari pulse-activating decoction capable of preventing radiation-induced heart injury. A preparation method comprises the following steps: adding water into radix astragali seu hedysari for decocting, and then filtering; concentrating filtrate till every 1ml filtrate is equivalent to 1 to 2g of raw medicinal material; precipitating with ethanol by two times, wherein the solution contains 75 percent of ethanol in the first time, the solution contains 85 percent of ethanol in the second time; recovering the ethanol and concentrating till every 1ml of ethanol is equivalent to 10g of the raw medicinal material; adding chrysanthemum indicum flower, fructus crataegi, semen raphanin, radix glycyrrhizae and wolfberry fruit and smashing; adding water for soaking, extracting, concentrating and recovering ethanol; adding honey, isomaltose and wine-related yeast species for performing initial fermentation; finally filtering, precipitating, sterilizing and tanking. The radix astragali seu hedysari pulse-activating decoction has the beneficial effects of effectively improving the cardiac function of an irradiated rat, lowering the serum levels of the troponin and creatine kinase-myocardial band (CK-MB) serving as heart injury symbolic molecules, adjusting signal molecules relevant to fibrosis injury such as extracellular matrix, reconstructed enzyme, inflammatory cytokines / chemotactic factor and TGF-beta, and effectively protecting irradiated heart.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicine, and relates to Huangqi Shengmai decoction for protecting radioactive heart damage. Background technique [0002] During radiotherapy for thoracic and abdominal tumors, the heart located in the mediastinum is inevitably irradiated and causes heart damage, which is called radiation-induced heart disease (RIHD). RIHD is the most common benign cause of death after radiotherapy for thoracic tumors, and its incidence is on the rise. The disease has gradually become a hot spot in medical research. The main pathological change of RIHD is fibrosis. Cardiac fibroblasts (CFs) are the main effector cells of cardiac fibrosis, which can synthesize and secrete TGF-β1 and collagen, which are directly involved in the pathological development of fibrosis. "Fibrosis" is considered to be a multifactorial complex disease of imbalanced expression of cytokines. Generally speaking, the pathogenesi...

AI Technical Summary

Problems solved by technology

Generally speaking, the pathogenesis of RIHD is unclear, and there are no reliable clinical treatment measures. Usually, prevention is the main focus. According to the analysis of the viewpoint of evidence-based medicine, "if there is evidence, use evidence, and if there is no evidence, use evidence to create evidence", the current clinical situation of RIHD is Prevention and treatment is in the stage of "no certificate" or "less certificate", which requires the practice of "creating and using certificates" on the basis of "verification", in-depth research on the pathological molecular mechanism of radiation-induced cardiac fibrosis injury, and finding possibilities for its clinical prevention and treatment intervention target, which has urgent practical significance